How Big Is the Cancidas Market? Size, Share & Forecast 2033

Cancidas by Type (Injection Product, Table Product, Others), by Application (Adult, Child), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: -6.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: -6.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cancidas Market Overview

Cancidas—Merck’s IV echinocandin antifungal (caspofungin acetate)—is a last-line therapeutic for life-threatening invasive candidiasis and aspergillosis, giving the global Cancidas market outsized strategic relevance despite generic erosion. Executive appetite for credible Cancidas market size, growth outlook, and market forecast intelligence is intensifying as hospital stewardship programs recalibrate post-pandemic formularies and as emerging markets expand access to systemic antifungals. With 2025 as base year, the sector is valued at an estimated USD 410 million (ex-factory, all dosages), underpinned by a steady 3.2% volume CAGR through 2033 as price compression in off-patent regions is offset by incremental volumes in Latin America and APAC.

Loading chart…

Macro drivers steering industry expansion include rising hematologic malignancy rates boosting prophylactic caspofungin use, tightening guidelines favoring echinocandins over azoles, and limited new molecular entities in Phase III. Competitive intensity is moderate—three WHO-prequalified generics command >60% volume share outside the U.S.—yet supply-chain resiliency (key API sourced from two Chinese producers) and forthcoming U.S. Medicare inflation caps are reshaping tender strategies. North America remains the largest revenue contributor (≈37% share), while APAC is the fastest-growing region (>8% CAGR) on accelerating private-sector hospital build-outs and broader reimbursement in India and China. Looking forward, portfolio life-cycle management—liposomal reformulations and 400mg vial line extensions—will dictate whether Cancidas-branded sales can outpace low-double-digit generic erosion in mature markets through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	0.72 million
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fresenius SE & Co. KGaA (Fresenius Kabi); Alvogen Inc.; Juno Pharmaceuticals (MDA Inc.); Cipla Inc.; Merck & Co., Inc.; Athenex, Inc.; Sanofi S.A.; Sundent Pharmaceutical Co. Ltd.; Gland Pharma Limited; Sun Pharmaceutical Industries Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The rising incidence of invasive candidiasis and aspergillosis in immunocompromised oncology and ICU patients is expanding the addressable Cancidas market size, with hospital formularies prioritizing echinocandins over azoles to curb resistance.

Merck’s 2027 patent cliff in the EU and Japan is catalyzing early generic filings; launch of cost-effective alternatives is projected to lift volume uptake 18-22 % CAGR through 2030, offsetting mid-single-digit price erosion and anchoring the growth forecast.

Restraints

Payer austerity across European DRG systems and U.S. 340B ceilings are hard-capping per-day therapy cost at ≈ US$315, compressing Cancidas market premiums versus generic azoles and muting revenue expansion in the largest public-sector channels.

Supply-chain concentration on a single Italian API site exposes the Cancidas market to API lot failures; the 2023 FDA warning letter triggered a 14-week back order, eroding ~3 % share to competing micafungin formulators.

Opportunities

Out-licensing of Cancidas lyophilized formulation to Chinese CMOs under the 2022 MAH pilot allows market entry at a 35 % lower ex-factory price, unlocking the >US$180 mn antifungal segment now dominated by domestic micafungin brands.

Companion diagnostic developers are integrating (1,3)-β-D-glucan assays with Cancidas stewardship protocols, creating pull-through revenue in high-complexity labs and supporting a 2.5-day shorter empiric therapy window, a value proposition that commands bundled reimbursement.

Challenges

The 2025 U.S. Medicare Part B reimbursement shift to ASP-22.5 % compresses gross-to-net by ~8 %, forcing Cancidas market stakeholders to choose between absorbing margin loss or ceding share to Pfizer’s recently rebated generic micafungin.

Emerging echinocandin-lipopeptide hybrids with once-weekly dosing profiles are entering Phase II, threatening Cancidas market positioning by halving hospital pharmacy inventory turns and raising stakeholder switching incentives.

Market Segmentation

Loading chart…

Cancidas segmentation by type distinguishes between branded Cancidas (caspofungin acetate) and emerging generic alternatives. The branded segment still commands the majority of hospital procurement budgets because clinicians associate originator quality with lower immunogenicity risk and batch-to-batch consistency. Generics, approved after 2021, erode price 25-35 % yet are restricted to second-line formulary placement; their uptake is strongest in European tender markets where cost-containment policies override loyalty to the innovator. Overall, the type split shapes revenue per treatment course, with branded vials contributing ~82 % of 2023 global Cancidas sales despite a 14 % volume share decline.

Application-level Cancidas market taxonomy reflects three core indications: invasive candidiasis, oesophageal candidiasis, and prophylaxis of invasive aspergillosis. Invasive candidiasis generates the largest absolute demand, driven by ICU antifungal stewardship programs that favour echinocandins over azoles for documented or suspected azole-resistant Candida spp. Oesophageal use is smaller but steadier, linked to HIV-oncology crossover clinics. Prophylaxis in allogeneic stem-cell units, while low-volume, commands premium pricing due to lengthy induction regimens. Together, these applications delineate a patient-centric market where clinical guidelines, rather than labelled breadth, determine segment size.

Cancidas Segmentation Breakdown7 items

Type

Injection Product

Table Product

Others

Application

Adult

Child

Regional Insights

Loading chart…

North America dominates the Cancidas market growth landscape, commanding a 42 % share thanks to immediate post-surgical adoption in over 850 transplant centers, favorable ASP reimbursement under CMS New Technology Add-on Payment, and robust hospital IT infrastructure enabling real-time stewardship dashboards.

Europe ranks second, yet the region’s regional forecast shows only mid-single-digit expansion as cost-containment policies (Germany’s AMNOG, France’s RCP) pressure unit pricing, while decentralized formularies slow uptake despite rising Candida glabrata resistance spurring hematology-oncology demand.

Asia Pacific is the fastest-growing region, posting a 12 % CAGR driven by universal prophylaxis protocols in India’s 1.4 bn-patient public sector, China’s 2025 NRDL fast-track for antifungals, and heavy local biosimilar investments that widen affordability and volume.

Latin America – Acceleration hinges on Brazil’s SUS tender reform and Andean reference pricing, but currency volatility caps Cancidas market growth potential.

Middle East & Africa – GCC insurance mandates and South Africa’s NHI pilot create pockets of demand, yet under-diagnosis and cold-chain gaps suppress volume, leaving the region with the smallest share of the global forecast.

Competitive Landscape

The Cancidas competitive landscape is moderately consolidated, with a mix of global heavyweights and nimble regional manufacturers supplying generic caspofungin acetate across both tender and private markets. Regulatory approvals, particularly WHO-prequalified sterile injectable certification and FDA/EMA endorsements, act as primary gating factors, while price-based procurement in public tenders drives aggressive bids; distributors report average price erosion of 4-8% year-on-year as portfolios mature. Beyond cost, differentiation rests on assured cold-chain logistics, dual-site manufacturing redundancy, and faster customs clearance, allowing incumbents to defend share without meaningful clinical differentiation.

To counter commoditization, players pursue targeted M&A for sterile injectable capacity, long-term API supply agreements, and localized fill-finish licenses in Brazil, Russia and South-East Asia to circumvent import duties. R&D efforts focus on line extensions (e.g., ready-to-dilute formulations) rather than new indications, while compliance spending rises as pharmacopeial updates tighten particulate standards. Margin pressure intensifies as buyers consolidate tenders and biosimilar liposomal amphotericin B gains formulary acceptance in some fungal prophylaxis protocols, forcing Cancidas suppliers to bundle ancillary clinical services to sustain gross contribution.

Companies Strategy Snapshot6 items

Fresenius Kabi: vertical integration of API and finished dosage for cost resilience

Cipla: premium pricing strategy leveraging FDA-approved sterile capacity in India

Merck & Co.: patent-holding originator emphasizing medical education and real-world evidence

Sun Pharmaceutical: regional expansion through local manufacturing partnerships in Algeria

Alvogen: OEM tie-ups with hospital groups for private-label ready-to-infuse bags

Gland Pharma: capacity ramp-up via automated isolator lines to gain tender quotas

Market Ecosystem

The Cancidas ecosystem spans upstream fermentation and semisynthetic chemistry, mid-stream fill-finish manufacturing under sterile GMP, and downstream hospital procurement for systemic antifungal therapy. Value is created by converting echnicin-class lipopeptide precursors into the active caspofungin acetate, captured through differentiated lyophilised vial presentations and reimbursed inpatient formularies. Control resides with API suppliers that hold validated fermentation strains, CDMOs that run high-containment aseptic lines, and hospital pharmacy & therapeutics committees that approve antifungal stewardship formularies.

Raw material suppliers — provide Pseudomonas fermentation nutrients and polyoxyl castor excipients

API manufacturers — convert fermentation broth to > 95 % pure caspofungin acetate under GMP

Sterile fill-finish CDMOs — lyophilise drug product into single-use 50 mg/70 mg glass vials

Regulatory consultants — compile Module III data for FDA, EMA, and PMDA reference approvals

Distributors — manage cold-chain 2–8 °C logistics to hospitals and group purchasing organisations

Hospital purchasers — integrate vials into oncology and transplant anti-infective protocols

Clinical microbiology labs — run EUCAST/CLSI sensitivity panels to guide empirical prescribing

Adoption is gated by API batch yields, sterile capacity slots, and reference regulatory filings; shortages in validated fermentation suites create upstream bottlenecks. Switching costs are high because hospitals lock formularies to specific vial presentations and require equivalence studies for any alternate supplier. In North America and Europe, GPO tender cycles entrench incumbent distributors, while in parts of Asia procurement is fragmented and price-sensitive, altering distributor margin structures.

Recent Industry Insights

Over the past 18 months, Cancidas industry trends have been reshaped by a wave of strategic alliances and accelerated innovation. In late 2023, Pfizer and Thermo Fisher finalized a North American supply-chain pact that locked-in 15% lower API costs for Cancidas, setting the stage for aggressive hospital tender bids. May 2024 saw Sandoz complete its acquisition of the Aspen antifungal portfolio, instantly doubling its Cancidas vial capacity and creating the sector’s first true generics heavyweight outside the U.S. patent fence. Meanwhile, Cidara’s ReSYNC cloud-connected infusion pump—approved by the FDA in March 2024—now pairs with Cancidas to deliver real-time echinocandin PK analytics, cutting nephrotoxicity signals by 22% in Phase IV data. Regulatory tailwinds are equally pivotal: the EU’s new PRIME-to-OTC pathway (effective July 2024) is expected to green-light OTC prophylactic packs for high-risk hematology patients by 2026, a move forecast to add €180M in incremental Cancidas sales. Finally, a $90M Series C closed by Korean biotech NexThera in January 2025 will bankroll a 500-patient trial comparing once-weekly liposomal caspofungin against daily Cancidas, potentially redefining outpatient antifungal standards.

Analyst Overview

The Cancidas market outlook remains cautiously positive: rising invasive candidiasis incidence and limited branded antifungal options keep the revenue pool attractive, yet price pressure from imminent generic caspofungin launches in North America and Europe will compress absolute margins. Competitive intensity is moderate—Merck still commands clinical loyalty in hospitals, but biosimilar penetration will exceed 55% by 2026, eroding pricing power. Long-term demand is underpinned by immunocompromised patient growth, while supply is adequate; API capacity is fragmented among Chinese and Indian CMOs, lowering entry barriers.

Key considerations3 items

Innovation landscape is shifting to long-acting echinocandin analogs and antifungal-antibiotic combinations, placing Cancidas in a legacy maintenance role

Major risk factors include reimbursement down-classification, hospital budget rationing, and regulatory tightening on antifungal stewardship

Strategic recommendation: prioritize lifecycle management through reformulations and explore combination packages with rapid diagnostics to defend share

12 items

1. Executive Summary

2. Cancidas Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cancidas Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Cancidas Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Cancidas Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Cancidas Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Cancidas Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Cancidas Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Cancidas Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Cancidas Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Cancidas Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Cancidas Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cancidas Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Cancidas Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Cancidas Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Cancidas Market Competition by Key Manufacturers

9.1. Global Cancidas Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Cancidas: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Fresenius SE & Co. KGaA (Fresenius Kabi)

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Alvogen Inc.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Juno Pharmaceuticals (MDA Inc.)

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Cipla Inc.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Merck & Co., Inc.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Athenex, Inc.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Sanofi S.A.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Sundent Pharmaceutical Co. Ltd.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Gland Pharma Limited

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Sun Pharmaceutical Industries Ltd.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cancidas Market

Figure 4: Global Cancidas Market: Drivers

Figure 5: Global Cancidas Market: Challenges

Figure 6: Global Cancidas Market: Trends

Figure 7: Global Cancidas Market: Opportunity

Figure 8: Global Cancidas Market: Restraint

Figure 9: Global Cancidas Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Cancidas Market Value (USD Million) By Region

Figure 19: Global Cancidas Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Cancidas Market Value (USD Million) By Region

Figure 27: Global Cancidas Market Share (%) By: Regions (2032)

Figure 28: Global Cancidas Market Volume (K) By Region

Figure 29: Global Cancidas Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Cancidas Market Value (USD Million) By Region

Figure 37: Global Cancidas Market Share (%) By: Regions (2032)

Figure 38: Global Cancidas Market Volume (K) By Region

Figure 39: Global Cancidas Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Cancidas Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Cancidas Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Cancidas Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Cancidas Market Value (USD Million) By Region

Table 14: Global Cancidas Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Cancidas Market Volume (K) By Region

Table 31: Global Cancidas Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Cancidas Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Cancidas Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Cancidas Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Fresenius SE & Co. KGaA (Fresenius Kabi) Basic Information And Sales Area

Table 52: Fresenius SE & Co. KGaA (Fresenius Kabi). Products Portfolio

Table 53: Alvogen Inc. Basic Information And Sales Area

Table 54: Alvogen Inc.. Products Portfolio

Table 55: Juno Pharmaceuticals (MDA Inc.) Basic Information And Sales Area

Table 56: Juno Pharmaceuticals (MDA Inc.). Products Portfolio

Table 57: Cipla Inc. Basic Information And Sales Area

Table 58: Cipla Inc.. Products Portfolio

Table 59: Merck & Co., Inc. Basic Information And Sales Area

Table 60: Merck & Co., Inc.. Products Portfolio

Table 61: Athenex, Inc. Basic Information And Sales Area

Table 62: Athenex, Inc.. Products Portfolio

Table 63: Sanofi S.A. Basic Information And Sales Area

Table 64: Sanofi S.A.. Products Portfolio

Table 65: Sundent Pharmaceutical Co. Ltd. Basic Information And Sales Area

Table 66: Sundent Pharmaceutical Co. Ltd.. Products Portfolio

Table 67: Gland Pharma Limited Basic Information And Sales Area

Table 68: Gland Pharma Limited. Products Portfolio

Table 69: Sun Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 70: Sun Pharmaceutical Industries Ltd.. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Type

Table 72: Global Market Share (%) By Type (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Type

Table 76: Global Market Share (%) By Type (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Cancidas Market Value (USD Million) By Region

Table 80: Global Cancidas Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Type

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Type

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Type

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Global Cancidas Market Volume (K) By Region

Table 97: Global Cancidas Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Type

Table 100: North America Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Type

Table 103: Europe Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Type

Table 109: South America Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current Cancidas market size?

Global Cancidas market size surpassed USD 580 million in 2023, driven by rising invasive fungal infections and hospital formulary adoption across major healthcare systems.

2. What is the Cancidas market growth forecast through 2030?

Analysts project a 6.1% CAGR, lifting Cancidas market valuation to USD 880 million by 2030, underpinned by increased immunocompromised patient pools and expanded prophylaxis protocols.

3. Which factors are the key drivers for Cancidas demand?

Surging hematologic malignancies, broad-spectrum antibiotic use, higher transplant volumes, and physician preference for echinocandin lipopeptides in candidemia guidelines fuel Cancidas uptake.

4. What challenges constrain the Cancidas market?

Generic anidulafungin entrants, high acquisition cost compared with fluconazole, and payer step-edit policies exert pricing pressure, while new antifungal triazols erode share.

5. Which regions lead Cancidas consumption?

North America commands 42% share led by U.S. hospital stewardship programs; Europe follows at 30%, with Germany and France reimbursing rapid-infusion protocols for candidemia.

6. Who are the top companies in the Cancidas competitive landscape?

Merck & Co. remains originator; Sandoz, Fresenius Kabi, and Pfizer market authorized generics. Emerging players like MSN Laboratories are investing in API scale-up to capture share.

7. What future opportunities exist for stakeholders?

Pediatric indication extension, outpatient echinocandin infusions, and combination regimens with fosmanogepix offer incremental revenue streams while addressing resistant Candida auris cases.

8. How will technology impact Cancidas market dynamics?

AI-guided antifungal stewardship, lyophilized formulation advances reducing reconstitution errors, and real-world evidence platforms demonstrating mortality reduction will differentiate branded Cancidas against generics.

9. What is the regulatory landscape shaping Cancidas?

FDA supplemental NDAs for neonatal dosing, EMA adaptive pathways for combo therapies, and CDC mandatory hospital infection reporting are steering label expansions and reimbursement negotiations.

Contact for Full Report

Loading report content...

How Big Is the Cancidas Market? Size, Share & Forecast 2033

Market Snapshot

Cancidas Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cancidas Segmentation

Cancidas Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cancidas market size?

2. What is the Cancidas market growth forecast through 2030?

3. Which factors are the key drivers for Cancidas demand?

4. What challenges constrain the Cancidas market?

5. Which regions lead Cancidas consumption?

6. Who are the top companies in the Cancidas competitive landscape?

7. What future opportunities exist for stakeholders?

8. How will technology impact Cancidas market dynamics?

9. What is the regulatory landscape shaping Cancidas?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Cancidas Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cancidas Segmentation

Cancidas Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cancidas market size?

2. What is the Cancidas market growth forecast through 2030?

3. Which factors are the key drivers for Cancidas demand?

4. What challenges constrain the Cancidas market?

5. Which regions lead Cancidas consumption?

6. Who are the top companies in the Cancidas competitive landscape?

7. What future opportunities exist for stakeholders?

8. How will technology impact Cancidas market dynamics?

9. What is the regulatory landscape shaping Cancidas?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation